Bausch Health (BHC) Companies provided an update on its financing plans. The Company announced that it has engaged J.P. Morgan in connection with the Company’s previously announced financing objectives. Any transactions would be subject to market and other conditions and there can be no assurance that the Company will be able to successfully complete any transaction on acceptable terms or at all.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health Companies: Uncertain Future Amid Xifaxan Dependency and Strategic Ambiguities
- Bausch Health: Navigating Market Risks Amid Uncertain Product Acceptance
- Bausch Health Reports Strong 2024 Growth Amid Challenges
- Bausch + Lomb price target lowered to $17 from $18 at BofA
- Bausch Health Reports Strong 2024 Financial Performance
Questions or Comments about the article? Write to editor@tipranks.com